Compare Incyte Corporation (INCY) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Veritone Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Veritone Inc trades at $1.55 (market cap $138.04M). The key difference: Incyte Corporation is far larger — about 177.8× Veritone Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| INCY | VERI | |
|---|---|---|
Market Cap | $24.54B | $138.04M |
Sector | Health | Technology |
52-Week High | $129.93 | $8.39 |
52-Week Low | $81.61 | $1.00 |
Enterprise Value | $20.04B | $170.07M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Veritone (VERI) trades at $1.52, up 5.56% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $111.73 million in 2025, with a negative net income margin of -123.76%, though revenue remains around $90-92 million. Recent news highlights partnerships in AI and public safety, but the stock faces headwinds from a securities class action lawsuit with a July 20, 2026 deadline.
The outlook is mixed: analyst consensus is evenly split between Buy and Hold ratings, but persistent losses and legal risks overshadow growth initiatives. Investment opportunity hinges on Veritone's ability to monetize its AI solutions and achieve profitability, while key risks include ongoing litigation and competitive pressures in the enterprise AI space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
